Manufacturers of : Bulk Drugs & Chemicals

Corporate Office: Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel .: 022-2407 2249 / 2401 9025 (30 Lines)

Fax.: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com website: www.aartidrugs.com CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2021-22 January 31, 2022

Listing/ Compliance Department **BSE** Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Listing/ Compliance Department National Stock Exchange of India Limited, "Exchange Plaza", Plot No. C/1, G Block Bandra - Kurla Complex, Bandra (East), Mumbai - 400051 **NSE CODE: AARTIDRUGS**

Dear Sir/Madam,

BSE CODE: 524348

Ref: Compliance of Regulation 33 and Regulation 30 of SEBI (LODR) Regulations, 2015.

Audited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021.

We wish to inform you that Board of Directors at its Meeting held on Monday, January 31, 2022, approved the Audited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021.

Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 we enclose the following:-

- Audited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021.
- Auditor's Report on Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021.

Further, please note that the Company has already made necessary arrangement to publish the same in the Newspapers as required under the SEBI (LODR) Regulations, 2015.

Meeting of the Board of Directors commenced at 12:00 Noon and concluded at 2:55 PM.

Kindly take the same on record. Thanking you,

Yours faithfully.

FOR AARTI DRUGS LIMITED

COMPANY SECRETARY

ICSI M. No.: A54527



AARTI DRUGS LIMITED STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st December' 2021 (Rs. in lakhs except for share data) Standalone Consolidated Quarter Ended Year Ended Quarter Ended Nine Months Ended Particulars 31st Dec 2021 30th Sep 2021 31st Dec 2020 31st Dec 2021 31st Dec 2020 31st Mar 2021 31st Dec 2021 31st Dec 2021 31st Dec 2020 Sr. 30th Sep 2021 31st Dec 2020 31st Mar 2021 (Audited) Revenue from operations 59,321 51,070 47,210 1,60,969 1,46,281 1,91,489 63,480 57,962 53,025 1,79,438 1,65,303 2,15,478 Other income 162 89 407 415 557 642 666 200 835 356 453 59,483 1,61,384 1.92.131 1.80.273 2.15.930 Total Income (I+II) 51.159 47.617 1.46.838 64,146 57.970 53.226 1.65.658 IV Expenses (a) Cost of materials consumed 38.781 35.085 27.025 1.08.793 85.139 1.12.779 41.680 38.614 29.603 1.19.528 92.017 1.22.152 (b) Purchase of stock-in-trade 1.296 1.118 996 4.319 2.987 4.317 2.152 2.503 2.337 8.478 8.465 11.124 (c) Changes in inventories of finished goods, (1,379 (2,103)408 (6,596)(258)(908)(1,889) (1,567)436 (6,885)(337)(1,172)work-in-progress and stock-in-trade (d) Employee benefits expense 1,760 1,695 1,708 5,125 5,232 6,929 2,091 2,060 1,985 6,128 6,057 8,050 2.296 (e) Finance costs 500 511 490 1,422 1.827 2.261 537 526 497 1.484 1.859 (f) Depreciation and amortisation expense 1,195 1,180 1,205 3,551 3,594 4,760 1,260 1,248 1,265 3,750 3,760 4,988 (g) Other expenses 9,794 8,361 7,292 25,920 20,893 28,246 10,446 8,979 8,088 27,846 23,484 31,613 Total expenses (IV) 51,948 45,847 39,124 1,42,535 1,19,414 1,58,383 56,277 52,362 44,211 1,60,328 1,35,304 1,79,052 Profit before exceptional items and tax (III - IV) 27,424 33,749 7,535 5,311 8,493 18,850 7,869 5,608 9,014 19,946 30,354 36,879 Exceptional items (22)(22 (22)(22)(22) (22 Profit before tax (V - VI) 7,535 5,311 8,516 18,850 27,447 33,771 7,869 5,608 9,037 19,946 30,377 36,901 VIII Tax Expenses Provision for taxation - Current 2,000 1,300 2,250 4,800 6,950 8,450 2,079 1,391 2,429 5,092 7,744 9,300 - MAT credit - Earlier year (150) Provision for deferred taxation (50 (50) (200)(250) (450) (38) (40)(195)(114)(242)(446) Total tax expenses (VIII) 1,950 1,250 2.050 4,650 6,700 8,000 2.041 1,350 2,234 4.978 7,502 8.862 Profit / (Loss) for the Year (VII - VIII) 5.585 4.061 6.466 14.200 20.747 25.771 5.828 4.258 6.803 14 968 22.875 28 040 Other Comprehensive Income Item that will not to be reclassified to statement of Profit and Loss Fair value changes on Investments, net 315 315 Remeasurement of defined benefit Liabiliy/Assets, net 26 26 ---Total Other Comprehensive Income,net 341 341 Total Comprehensive Income for the Year (IX+X) 5,585 4.061 6.466 14,200 20.747 26,112 5.828 4.258 6.803 14.968 22.875 28,381 Weighted average number of equity shares used for computing earning per share (face value of Rs.10 each) 9.260 9.260 9.320 9.260 9.320 9.320 9.260 9.260 9.320 9.260 9.320 9.320 Profit attributable to : XIII Owner of the Company 5,585 4,061 6,466 14,200 20,747 25,771 5.829 4,259 6.804 14.970 22.876 28.041 Non- Controlling Interest (0.65)(1.36)(0.46)(2.15)(0.93)(1.47)Total Comprehensive Income attributable to: XIV Owner of the Company 5.585 4,061 6.466 14,200 20.747 26.112 5.829 4.259 6.804 14.970 22.876 28.382 Non- Controlling Interest (0.65)(1.36)(0.46)(2.15)(0.93)(1.47)Earning per equity share (in Rs.) (not annualised) ΧV 30.09 1) Basic 6.03 4.39 6.94 22.26 27.65 6.29 4.60 7.30 16.14 24.54 15.31 (2) Diluted 6.03 4.39 6.94 22.26 27 65 6.29 7.30 16.14 24.54 30.09

Notes:

- The above results for the quarter and nine months ended 31st December, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 31st January, 2022.
- 2 The Board of Directors have recommended an Interim Dividend of Rs.1/- per Equity Share of Rs. 10/- each (10%) amounting to Rs.92600000/- for the Period ended 31st December 2021.
- 3 Company has only one business segment i.e. pharmaceuticals.
- 4 Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- 5 The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of

Place: Mumbai Date: 31st January' 2022 For AARTI DRUGS LIMITED

HARSHIT M. SAVLA (Jt. Managing Director)



INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF AARTI DRUGS LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly financial results of Aarti Drugs Limited ("the company") for the quarter ended December 31, 2021 and the year-to-date results for the period from April 01, 2021 to December 31, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended December 31, 2021 as well as the year-to-date results for the period from April 01, 2021 to December 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year-to-date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Kirtane & Pandit LLP, Chartered Accountants FRN: 105215W/W100057

Milind Bhave

Partner M No. 047973

UDIN: 22047973AAAAAB1032

105215W/ W100057

Place: Mumbai.

Date: January 31, 2022



INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF AARTI DRUGS LIMITED

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of Aarti Drugs Limited ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group") for the quarter ended December 31, 2021 and for the period from April 01, 2021 to December 31, 2021 ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/financial information of subsidiaries, the Statement:

- a. includes the results of the following entities:
- i. Pinnacle Life Science Private Limited (Wholly-owned Subsidiary Company)
- ii. Aarti Speciality Chemicals Limited (Wholly-owned Subsidiary Company)
- iii. Pinnacle Chile SPA (Subsidiary Company)
- b. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net profit) and other comprehensive income and other financial information for the Group for the guarter ended and nine months ended December 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Consolidated Financial Results

These consolidated financial results have been prepared on the basis of the annual financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

We did not audit the interim financial information of 2 subsidiaries include in the Consolidated Financial Results, whose interim Financial Statements / Financial Results / Financial Information reflect total revenue of ₹ 5,486.30 Lakhs and ₹ 21,711.19 Lakhs for the quarter and nine months ended December 31, 2021 respectively, total net profit after tax of ₹ 253.15 Lakhs and ₹ 893.74 Lakhs for the quarter and nine months ended December 31, 2021 respectively, as considered in the Consolidated Financial Results. These interim Financial Statements / Financial Results / Financial Information have been audited by other auditors. The independent auditors' reports on interim Financial Statements / Financial Results / Financial Information of these entities have been furnished to us and our opinion on the Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

The Consolidated Financial Results include the interim Financial Results of a Subsidiary Company which have not been audited by their auditors, whose interim Financial Statements / Financial Results / Financial Information reflect, total revenue of Nil and Nil for the quarter and nine months ended December 31, 2021 respectively, total net loss of ₹ 13.02 Lakhs and ₹ 43.06 Lakhs for the quarter and nine months ended December 31, 2021 respectively, as considered in the Consolidated Financial



Results. The unaudited interim Financial Statements / Financial Results / Financial Information have been furnished to us by the Board of Directors and our opinion on the Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of this Subsidiary Company is based solely on such unaudited interim Financial Statements / Financial Results / Financial Information. In our opinion and according to the information and explanations given to us by the Board of Directors, the interim Financial Statements / Financial Results / Financial Information are not material to the Group.

Our opinion on the Consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results / Financial Information certified by the Board of Directors.

For Kirtane & Pandit LLP, Chartered Accountants

FRN: 105215W/W100057

Milind Bhave Partner M No. 047973

UDIN: 22047973AAAAAC3454

Place: Mumbai

Date: January 31, 2022